Investigadores
Inicio
Investigadores
Banc de Sang i Teixits (BST). Barcelona.
Inmunoterapia Celular (células CAR)
Terapia de células somáticas y medicina regenerativa
Desarrollos Tecnológicos y Terapéuticos
Joaquim VIVES ARMENGOL
Investigador principal
Grupo de Investigación: Banc de Sang i Teixits (BST). Barcelona.
Joaquín Delgadillo Duarte
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST). Barcelona.
Luciano Rodríguez Gómez
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST). Barcelona.
Ruth Coll Bonet
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST). Barcelona.
Bayes-Genis A., Gastelurrutia P., Monguió-Tortajada M., Cámara M.L., Prat-Vidal C., Cediel G., Rodríguez-Gómez L., Teis A., Revuelta-López E., Ferrer-Curriu G., Roura S., Gálvez-Montón C., Bisbal F., Vives J., Vilarrodona A., Muñoz-Guijosa C., Querol S.. Implantation of a double allogeneic human engineered tissue graft on damaged heart: insights from the PERISCOPE phase I clinical trial. eBioMedicine. April 2024. DOI: 10.1016/j.ebiom.2024.105060.
Impacto: 11.1. Cuartil: Q1
(1er decil)
Bayes-Genis A., Gastelurrutia P., Monguió-Tortajada M., Cámara M.L., Prat-Vidal C., Cediel G., Rodríguez-Gómez L., Teis A., Revuelta-López E., Ferrer-Curriu G., Roura S., Gálvez-Montón C., Bisbal F., Vives J., Vilarrodona A., Muñoz-Guijosa C., Querol S.. Implantation of a double allogeneic human engineered tissue graft on damaged heart: insights from the PERISCOPE phase I clinical trial. eBioMedicine. April 2024. DOI: 10.1016/j.ebiom.2024.105060.
Impacto: 11.1. Cuartil: Q1
(1er decil)
López-Fernández A., Garcia-Gragera V., Lecina M., Vives J.. Identification of critical process parameters for expansion of clinical grade human Wharton's jelly-derived mesenchymal stromal cells in stirred-tank bioreactors. Biotechnology Journal. February 2024. DOI: 10.1002/biot.202300381.
Impacto: 4.7. Cuartil: Q1
Sanchez-Guijo F., Vives J., Ruggeri A., Chabannon C., Corbacioglu S., Dolstra H., Farge D., Gagelmann N., Horgan C., Kuball J., Neven B., Rintala T., Rocha V., Sanchez-Ortega I., Snowden J.A., Zwaginga J.J., Gnecchi M., Sureda A.. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT). Cytotherapy. 2024. DOI: 10.1016/j.jcyt.2024.02.007.
Impacto: 4.5. Cuartil: Q2
Cabrera-Pérez R., Ràfols-Mitjans A., Roig-Molina Á., Beltramone S., Vives J., Batlle-Morera L.. Human Wharton’s jelly-derived mesenchymal stromal cells promote bone formation in immunodeficient mice when administered into a bone microenvironment. Journal of Translational Medicine. December 2023. DOI: 10.1186/s12967-023-04672-9.
Delgadillo J., Kerkelä E., Waters A., Akker E.v.d., Lechanteur C., Baudoux E., Gardiner N., De Vos J., Vives J.. A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe. Cytotherapy. December 2023. DOI: 10.1016/j.jcyt.2023.08.001.
Impacto: 4.5. Cuartil: Q2
Kuebler B., Alvarez-Palomo B., Aran B., Castaño J., Rodriguez L., Raya A., Querol Giner S., Veiga A.. Generation of a bank of clinical-grade, HLA-homozygous iPSC lines with high coverage of the Spanish population. Stem Cell Research and Therapy. December 2023. DOI: 10.1186/s13287-023-03576-1.
Impacto: 7.5. Cuartil: Q1
Vives J., Sánchez-Guijo F., Gnecchi M., Zwaginga J.J.. Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe. Cytotherapy. October 2023. DOI: 10.1016/j.jcyt.2023.06.006.
Impacto: 4.5. Cuartil: Q2
Guarga L., Paco N., Manchon-Walsh P., Vela E., Delgadillo J., Pontes C., Borràs J.M.. Management, Survival, and Costs of Pancreatic Cancer: Population-Based Observational Study in Catalonia. International Journal of Environmental Research and Public Health. May 2023. DOI: 10.3390/ijerph20095673.
Impacto: 4.614. Cuartil: Q1
Sánchez-Guijo F., Avendaño-Solá C., Badimón L., Bueren J.A., Canals J.M., Delgadillo J., Delgado J., Eguizábal C., Fernández-Santos M.E., García-Olmo D., González-Aseguinolaza G., Juan M., Martín F., Mata R., Montserrat N., Pérez-Martínez A., Pérez-Simón J.A., Prósper F., Urbano-Ispizua Á., Zapata A.G., Sureda A., Moraleda J.M.. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV). Bone Marrow Transplantation. 2023. DOI: 10.1038/s41409-023-01962-0.
Impacto: 5.174. Cuartil: Q2
Fernandez-Sojo J., Delgadillo J., Vives J., Rodriguez L., Mendoza A., Azqueta C., Garcia-Buendia A., Valdivia E., Martorell L., Rubio-Lopez N., Linares M., Alonso S., Ancochea A., García-Rey E., García-Muñoz N., Medina L., Querol S.. A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank experience. Cytotherapy. January 2023. DOI: 10.1016/j.jcyt.2022.07.011.
Impacto: 6.196. Cuartil: Q1
Torrents S., del Moral A.E., Codinach M., Rodríguez L., Querol S., Vives J.. Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use. Immunologic Research. 2023. DOI: 10.1007/s12026-023-09385-1.
Impacto: 4.505. Cuartil: Q3
Torrents S., Grau-Vorster M., Vives J.. Illustrative Potency Assay Examples from Approved Therapies. Advances in Experimental Medicine and Biology. 2023. DOI: 10.1007/978-3-031-30040-0_9.
Impacto: 3.65. Cuartil: Q2
Martorell L., López-Fernández A., García-Lizarribar A., Sabata R., Gálvez-Martín P., Samitier J., Vives J.. Preservation of critical quality attributes of mesenchymal stromal cells in 3D bioprinted structures by using natural hydrogel scaffolds. Biotechnology and Bioengineering. 2023. DOI: 10.1002/bit.28381.
Impacto: 4.395. Cuartil: Q2
Torrents S., Grau-Vorster M., Vives J.. Potency Assays: The ‘Bugaboo’ of Stem Cell Therapy. Advances in Experimental Medicine and Biology. 2023. DOI: 10.1007/978-3-031-30040-0_3.
Impacto: 3.65. Cuartil: Q2
López-Fernández A., Codinach M., Coca M.I., Prat-Vidal C., Castaño J., Torrents S., Aran G., Rodríguez L., Querol S., Vives J.. Comparability exercise of critical quality attributes of clinical-grade human mesenchymal stromal cells from the Wharton's jelly: single-use stirred tank bioreactors versus planar culture systems. Cytotherapy. 2023. DOI: 10.1016/j.jcyt.2023.08.008.
Impacto: 4.5. Cuartil: Q2
Guarga L., Paco N., Vela E., Clèries M., Corral J., Delgadillo J., Pontes C., Borràs J.M.. Changes in Treatment Patterns and Costs for Lung Cancer Have Not Resulted in Relevant Improvements in Survival: A Population-Based Observational Study in Catalonia. Cancers. December 2022. DOI: 10.3390/cancers14235791.
Impacto: 6.575. Cuartil: Q1
Muñoz-Domínguez N., Carreras-Sánchez I., López-Fernández A., Vives J.. Optimisation of processing methods to improve success in the derivation of human multipotent mesenchymal stromal cells from cryopreserved umbilical cord tissue fragments. Cryobiology. October 2022. DOI: 10.1016/j.cryobiol.2022.08.002.
Impacto: 2.728. Cuartil: Q3
Lopez-Navas L., Torrents S., Sánchez-Pernaute R., Vives J.. Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies. Stem Cells Translational Medicine. August 2022. DOI: 10.1093/stcltm/szac046.
Impacto: 7.655. Cuartil: Q1
Vives J., Hernández J., Mirabel C., Puigdomenech‐poch M., Romeo‐guitart D., Marmolejo‐martínez‐artesero S., Cabrera‐pérez R., Jaramillo J., Kumru H., García‐lópez J., Vidal‐samsó J., Navarro X., Coll‐bonet R.. Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton’s Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance. Cells. July-2 2022. DOI: 10.3390/cells11142153.
Impacto: 7.666. Cuartil: Q2
Vives J., Sòria M.G., McGrath E., Magri M.. The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance. Cells. July-1 2022. DOI: 10.3390/cells11132112.
Impacto: 7.666. Cuartil: Q2
Chaverri D., Vivas D., Gallardo-Villares S., Granell-Escobar F., Pinto J.A., Vives J.. A pilot study of circulating levels of TGF-β1 and TGF-β2 as biomarkers of bone healing in patients with non-hypertrophic pseudoarthrosis of long bones. Bone Reports. June 2022. DOI: 10.1016/j.bonr.2021.101157.
Guarga L., Gasol M., Reyes A., Roig M., Alonso E., Clopés A., Delgadillo J.. Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia (Spain). Value in Health. May 2022. DOI: 10.1016/j.jval.2021.10.010.
Impacto: 5.101. Cuartil: Q1
(1er decil)
Rebulla P., Querol S., Pupella S., Prati D., Delgadillo J., De Angelis V.. Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain. Frontiers in Cell and Developmental Biology. 4 January 2022. DOI: 10.3389/fcell.2021.812038.
Impacto: 5.5. Cuartil: Q1
Samarkanova D., Cox S., Hernandez D., Rodriguez L., Pérez M.L., Madrigal A., Vilarrodona A., Querol S., Casaroli-Marano R.P.. Cord blood and amniotic membrane extract eye drop preparations display immune-suppressive and regenerative properties. Scientific Reports. December 2021. DOI: 10.1038/s41598-021-93150-7.
Impacto: 4.996. Cuartil: Q2
Guarga L., Ameijide A., Marcos-Gragera R., Carulla M., Delgadillo J., Borràs J.M., Galceran J.. Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Scientific Reports. December 2021. DOI: 10.1038/s41598-021-02582-8.
Impacto: 4.996. Cuartil: Q2
Reyes-Travé A., Guarga-Solé L., Roig-Izquierdo M., Alonso-Pérez E., Clopés-Estela A., Delgadillo-Duarte J.. Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia. PharmacoEconomics. September 2021. DOI: 10.1007/s40273-021-01046-1.
Impacto: 4.558. Cuartil: Q1
Muñoz-Domínguez N., Roura S., Prat-Vidal C., Vives J.. Wharton’s jelly mesenchymal stromal cells and derived extracellular vesicles as post-myocardial infarction therapeutic toolkit: An experienced view. Pharmaceutics. September 2021. DOI: 10.3390/pharmaceutics13091336.
Impacto: 6.525. Cuartil: Q1
Samarkanova D., Martin S., Bisbe L., Puig J., Calatayud-Pinuaga M., Rodriguez L., Azqueta C., Coll R., Casaroli-Marano R., Madrigal A., Rebulla P., Querol S.. Clinical evaluation of allogeneic eye drops from cord blood platelet lysate. Blood Transfusion. July 2021. DOI: 10.2450/2020.0130-20.
Impacto: 5.752. Cuartil: Q2
García-Muñoz E., Vives J.. Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use. Cytotechnology. June 2021. DOI: 10.1007/s10616-021-00474-3.
Impacto: 2.04. Cuartil: Q4
Garcia-Lopez J., Delgadillo J., Vilarrodona A., Querol S., Ovejo J., Coll R., Millan A., Madrigal A., Soria G., Vidal F., Vives J., Herrero M.J., Lopez I., Sauleda S., Contreras E., Grifols J.R., Guasch R., Tahull E., Puig L., Masip A., Argelagués E., Muñiz-Diaz E.. SARS-CoV-2/COVID-19 pandemic: First wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. Blood Transfusion. March 2021. DOI: 10.2450/2021.0259-20.
Impacto: 5.752. Cuartil: Q2
Gastelurrutia P., Prat-Vidal C., Vives J., Coll R., Bayes-Genis A., Gálvez-Montón C.. Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience. Frontiers in Cardiovascular Medicine. 4 February 2021. DOI: 10.3389/fcvm.2021.604434.
Impacto: 5.846. Cuartil: Q2
Albu S., Kumru H., Coll R., Vives J., Vallés M., Benito-Penalva J., Rodríguez L., Codinach M., Hernández J., Navarro X., Vidal J.. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. February 2021. DOI: 10.1016/j.jcyt.2020.08.008.
Impacto: 6.196. Cuartil: Q1
Ramallo M., Carreras-Sánchez I., López-Fernández A., Vélez R., Aguirre M., Feldman S., Vives J.. Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord. Histology and Histopathology. January 2021. DOI: 10.14670/HH-18-249.
Impacto: 2.13. Cuartil: Q3
Carreras-Sánchez I., López-Fernández A., Rojas-Márquez R., Vélez R., Aguirre M., Vives J.. Derivation of Mesenchymal Stromal Cells from Ovine Umbilical Cord Wharton's Jelly. Current Protocols. January 2021. DOI: 10.1002/cpz1.18.
Vives J., Rodríguez L., Coca M.I., Reales L., Cabrera-Pérez R., Martorell L.. Use of Multipotent Mesenchymal Stromal Cells, Fibrin, and Scaffolds in the Production of Clinical Grade Bone Tissue Engineering Products. Methods in Molecular Biology. 2021. DOI: 10.1007/7651_2020_280.
García de Frutos A., González-Tartière P., Coll Bonet R., Ubierna Garcés M.T., del Arco Churruca A., Rivas García A., Matamalas Adrover A., Saló Bru G., Velazquez J.J., Vila-Canet G., García-Lopez J., Vives J., Codinach M., Rodriguez L., Bagó Granell J., Càceres Palou E.. Randomized clinical trial: expanded autologous bone marrow mesenchymal cells combined with allogeneic bone tissue, compared with autologous iliac crest graft in lumbar fusion surgery. Spine Journal. December 2020. DOI: 10.1016/j.spinee.2020.07.014.
Impacto: 4.166. Cuartil: Q1
López-Fernández A., Barro V., Ortiz-Hernández M., Manzanares M.C., Vivas D., Vives J., Vélez R., Ginebra M.P., Aguirre M.. Effect of Allogeneic Cell-Based Tissue-Engineered Treatments in a Sheep Osteonecrosis Model. Tissue Engineering - Part A. September 2020. DOI: 10.1089/ten.tea.2019.0339.
Impacto: 3.845. Cuartil: Q2
García-Fernández C., López-Fernández A., Borrós S., Lecina M., Vives J.. Strategies for large-scale expansion of clinical-grade human multipotent mesenchymal stromal cells. Biochemical Engineering Journal. 15 July 2020. DOI: 10.1016/j.bej.2020.107601.
Impacto: 3.978. Cuartil: Q2
Vivas D., Grau-Vorster M., Oliver-Vila I., García-López J., Vives J.. Evaluation of a cell-based osteogenic formulation compliant with good manufacturing practice for use in tissue engineering. Molecular Biology Reports. 1 July 2020. DOI: 10.1007/s11033-020-05588-z.
Impacto: 2.316. Cuartil: Q4
Vives J., Casademont-Roca A., Martorell L., Nogués N.. Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines. Bone Marrow Transplantation. 1 July 2020. DOI: 10.1038/s41409-020-0822-8.
Impacto: 5.483. Cuartil: Q1
Samarkanova D., Cox S., Hernandez D., Rodriguez L., Casaroli-Marano R.P., Madrigal A., Querol S.. Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine. Frontiers in Immunology. 27 May 2020. DOI: 10.3389/fimmu.2020.00942.
Impacto: 7.561. Cuartil: Q1
Samarkanova D., Rodríguez L., Vives J., Coll R., Tahull E., Azqueta C., Valdivia E., Codinach M., Farssac E., Gaitan J., Escudero J.R., Querol S.. Cord blood-derived platelet concentrates as starting material for new therapeutic blood components prepared in a public cord blood bank: From product development to clinical application. Blood Transfusion. May 2020. DOI: 10.2450/2020.0305-19.
Impacto: 3.443. Cuartil: Q2
Prat-Vidal C., Rodríguez-Gómez L., Aylagas M., Nieto-Nicolau N., Gastelurrutia P., Agustí E., Gálvez-Montón C., Jorba I., Teis A., Monguió-Tortajada M., Roura S., Vives J., Torrents-Zapata S., Coca M.I., Reales L., Cámara-Rosell M.L., Cediel G., Coll R., Farré R., Navajas D., Vilarrodona A., García-López J., Muñoz-Guijosa C., Querol S., Bayes-Genis A.. First-in-human PeriCord cardiac bioimplant: Scalability and GMP manufacturing of an allogeneic engineered tissue graft. EBioMedicine. April 2020. DOI: 10.1016/j.ebiom.2020.102729.
Impacto: 8.143. Cuartil: Q1
Vives J., Batlle-Morera L.. The challenge of developing human 3D organoids into medicines. Stem Cell Research and Therapy. 4 March 2020. DOI: 10.1186/s13287-020-1586-1.
Impacto: 6.832. Cuartil: Q1
Grau-Vorster M., López-Montañés M., Cantó E., Vives J., Oliver-Vila I., Barba P., Querol S., Rudilla F.. Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy. Frontiers in Immunology. 25 February 2020. DOI: 10.3389/fimmu.2020.00271.
Impacto: 7.561. Cuartil: Q1
Cabrera-Pérez R., Monguió-Tortajada M., Gámez-Valero A., Rojas-Márquez R., Borràs F.E., Roura S., Vives J.. Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: Mechanisms and implications for bioprocess development and clinical application. Stem Cell Research and Therapy. 28 November 2019. DOI: 10.1186/s13287-019-1450-3.
Impacto: 5.116. Cuartil: Q1
Grau-Vorster M., Laitinen A., Nystedt J., Vives J.. HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: A two-site study. Stem Cell Research and Therapy. 13 June 2019. DOI: 10.1186/s13287-019-1279-9.
Impacto: 5.116. Cuartil: Q1
Roura S., Vives J.. Extracellular vesicles: Squeezing every drop of regenerative potential of umbilical cord blood. Metabolism: Clinical and Experimental. June 2019. DOI: 10.1016/j.metabol.2019.02.006.
Impacto: 6.159. Cuartil: Q1
Grau-Vorster M., Rodríguez L., Del Mazo-Barbara A., Mirabel C., Blanco M., Codinach M., Gómez S.G., Querol S., García-López J., Vives J.. Compliance with good manufacturing practice in the assessment of immunomodulation potential of clinical grade multipotent mesenchymal stromal cells derived from wharton’s jelly. Cells. May 2019. DOI: 10.3390/cells8050484.
Impacto: 4.366. Cuartil: Q2
Alvarez-Palomo B., Vives J., Casaroli-Marano R.P., Gomez S.G., Rodriguez Gómez L., Edel M.J., Giner S.Q.. Adapting cord blood collection and banking standard operating procedures for HLA-Homozygous induced pluripotent stem cells production and banking for clinical application. Journal of Clinical Medicine. April 2019. DOI: 10.3390/jcm8040476.
Impacto: 3.303. Cuartil: Q1
Vives J., Mirabel C.. Multipotent Mesenchymal Stromal Cells From Bone Marrow for Current and Potential Clinical Applications. Encyclopedia of Tissue Engineering and Regenerative Medicine: Volumes 1-3. 1 January 2019. DOI: 10.1016/B978-0-12-801238-3.65506-X.
Vives J., Mirabel C.. Multipotent mesenchymal stromal cells from bone marrow for current and potential clinical applications. Encyclopedia of Tissue Engineering and Regenerative Medicine. 1 January 2019. DOI: 10.1016/B978-0-12-801238-3.65506-X.
GRAU-VORSTER M., RODRÍGUEZ L., TORRENTS-ZAPATA S., VIVAS D., CODINACH M., BLANCO M., OLIVER-VILA I., GARCÍA-LÓPEZ J.O.A.N., VIVES J.. Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow–derived multipotent mesenchymal stromal cell expansion cultures. Cytotherapy. January 2019. DOI: 10.1016/j.jcyt.2018.09.009.
Impacto: 4.218. Cuartil: Q1
Mirabel C., Puente-Massaguer E., Del Mazo-Barbara A., Reyes B., Morton P., Gòdia F., Vives J.. Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products. Journal of Translational Medicine. 24 October 2018. DOI: 10.1186/s12967-018-1659-4.
Impacto: 4.098. Cuartil: Q2
Navarro-Valverde C., Caballero-Villarraso J., Mata-Granados J.M., Casado-Díaz A., Sosa-Henríquez M., Malouf-Sierra J., Nogués-Solán X., Rodríguez-Mañas L., Cortés-Gil X., Delgadillo-Duarte J., Quesada-Gómez J.M.. High Serum Retinol as a Relevant Contributor to Low Bone Mineral Density in Postmenopausal Osteoporotic Women. Calcified Tissue International. 1 June 2018. DOI: 10.1007/s00223-017-0379-8.
Impacto: 3.265. Cuartil: Q2
Vivas D., Caminal M., Oliver-Vila I., Vives J.. Derivation of Multipotent Mesenchymal Stromal Cells from Ovine Bone Marrow. Current Protocols in Stem Cell Biology. 1 February 2018. DOI: 10.1002/cpsc.43.
Oliver-Vila I., Ramírez-Moncayo C., Grau-Vorster M., Marín-Gallén S., Caminal M., Vives J.. Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells. Cytotechnology. 1 February 2018. DOI: 10.1007/s10616-017-0186-0.
Impacto: 1.672. Cuartil: Q3
Prat S., Gallardo-Villares S., Vives M., Carreño A., Caminal M., Oliver-Vila I., Chaverri D., Blanco M., Codinach M., Huguet P., Ramírez J., Pinto J.A., Aguirre M., Coll R., Garcia-López J., Granell-Escobar F., Vives J.. Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis. Journal of Tissue Engineering and Regenerative Medicine. January 2018. DOI: 10.1002/term.2323.
Impacto: 3.319. Cuartil: Q2
Chaverri D., Vives J.. Toward the clinical use of circulating biomarkers predictive of bone union. Biomarkers in Medicine. December 2017. DOI: 10.2217/bmm-2017-0180.
Impacto: 2.346. Cuartil: Q3
Caminal M., Vélez R., Rabanal R.M., Vivas D., Batlle-Morera L., Aguirre M., Barquinero J., García J., Vives J.. A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies. Journal of Tissue Engineering and Regenerative Medicine. December 2017. DOI: 10.1002/term.2254.
Impacto: 4.089. Cuartil: Q1
Roura S., Gálvez-Montón C., Mirabel C., Vives J., Bayes-Genis A.. Mesenchymal stem cells for cardiac repair: Are the actors ready for the clinical scenario?. Stem Cell Research and Therapy. 27 October 2017. DOI: 10.1186/s13287-017-0695-y.
Impacto: 4.963. Cuartil: Q1
Reyes B., Coca M.I., Codinach M., López-Lucas M.D., del Mazo-Barbara A., Caminal M., Oliver-Vila I., Cabañas V., Lope-Piedrafita S., García-López J., Moraleda J.M., Fontecha C.G., Vives J.. Assessment of biodistribution using mesenchymal stromal cells: Algorithm for study design and challenges in detection methodologies. Cytotherapy. September 2017. DOI: 10.1016/j.jcyt.2017.06.004.
Impacto: 3.993. Cuartil: Q1
Casamayor-Genescà A., Pla A., Oliver-Vila I., Pujals-Fonts N., Marín-Gallén S., Caminal M., Pujol-Autonell I., Carrascal J., Vives-Pi M., Garcia J., Vives J.. Clinical-scale expansion of CD34<sup>+</sup> cord blood cells amplifies committed progenitors and rapid scid repopulation cells. New Biotechnology. 25 March 2017. DOI: 10.1016/j.nbt.2016.10.011.
Impacto: 3.733. Cuartil: Q1
Jubert N.J., Rodríguez L., Reverté-Vinaixa M.M., Navarro A.. Platelet-rich plasma injections for advanced knee osteoarthritis: A prospective, randomized, double-blinded clinical trial. Orthopaedic Journal of Sports Medicine. February 2017. DOI: 10.1177/2325967116689386.
Del Mazo-Barbara A., Mirabel C., Nieto V., Reyes B., García-López J., Oliver-Vila I., Vives J.. Qualification of computerized monitoring systems in a cell therapy facility compliant with the good manufacturing practices. Regenerative Medicine. September 2016. DOI: 10.2217/rme-2016-0066.
Impacto: 2.868. Cuartil: Q2
Codinach M., Blanco M., Ortega I., Lloret M., Reales L., Coca M., Torrents S., Doral M., Oliver-Vila I., Requena-Montero M., Vives J., Garcia-López J.. Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow–derived multipotent mesenchymal stromal cells. Cytotherapy. 1 September 2016. DOI: 10.1016/j.jcyt.2016.05.012.
Impacto: 3.203. Cuartil: Q2
Del Mazo-Barbara A., Nieto V., Mirabel C., Reyes B., García-López J., Oliver-Vila I., Vives J.. Streamlining the qualification of computerized systems in GxP-compliant academic cell therapy facilities. Cytotherapy. 1 September 2016. DOI: 10.1016/j.jcyt.2016.06.003.
Impacto: 3.203. Cuartil: Q2
Caminal M., Peris D., Fonseca C., Barrachina J., Codina D., Rabanal R., Moll X., Morist A., García F., Cairó J., Gòdia F., Pla A., Vives J.. Cartilage resurfacing potential of PLGA scaffolds loaded with autologous cells from cartilage, fat, and bone marrow in an ovine model of osteochondral focal defect. Cytotechnology. 1 August 2016. DOI: 10.1007/s10616-015-9842-4.
Impacto: 1.857. Cuartil: Q3
Soler R., Orozco L., Munar A., Huguet M., López R., Vives J., Coll R., Codinach M., Garcia-Lopez J.. Final results of a phase I–II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration. Knee. 1 August 2016. DOI: 10.1016/j.knee.2015.08.013.
Impacto: 1.976. Cuartil: Q2
Martinez-Zapata M.J., Martí-Carvajal A.J., Solà I., Expósito J.A., Bolíbar I., Rodríguez L., Garcia J., Zaror C.. Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database of Systematic Reviews. 25 May 2016. DOI: 10.1002/14651858.CD006899.pub3.
Impacto: 6.124. Cuartil: Q1
(1er decil)
Oliver-Vila I., Coca M., Grau-Vorster M., Pujals-Fonts N., Caminal M., Casamayor-Genescà A., Ortega I., Reales L., Pla A., Blanco M., García J., Vives J.. Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton's jelly. Cytotherapy. 1 January 2016. DOI: 10.1016/j.jcyt.2015.10.001.
Impacto: 3.203. Cuartil: Q2
Milián E., Prats E., Cairó J., Gòdia F., Vives J.. BHRF1 exerts an antiapoptotic effect and cell cycle arrest via Bcl-2 in murine hybridomas. Journal of Biotechnology. September 01, 2015. DOI: 10.1016/j.jbiotec.2015.06.379.
Impacto: 2.667. Cuartil: Q2
Ballester M., Roig E., Gich I., Puntes M., Delgadillo J., Santos B., Antonijoan R.. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure. Drug Design, Development and Therapy. 5 August 2015. DOI: 10.2147/DDDT.S86300.
Impacto: 2.881. Cuartil: Q2
Vives J., Oliver-Vila I., Pla A.. Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments. Cytotherapy. 1 August 2015. DOI: 10.1016/j.jcyt.2015.02.002.
Impacto: 3.625. Cuartil: Q1
Vives J., Carmona G.. Guide to Cell Therapy GxP: Quality Standards in the Development of Cell-Based Medicines in Non-pharmaceutical Environments. Guide to Cell Therapy GxP: Quality Standards in the Development of Cell-Based Medicines in Non-pharmaceutical Environments. 1 January 2015. DOI: .
Caminal M., Fonseca C., Peris D., Moll X., Rabanal R.M., Barrachina J., Codina D., García F., Cairó J.J., Gòdia F., Pla A., Vives J.. Use of a chronic model of articular cartilage and meniscal injury for the assessment of long-term effects after autologous mesenchymal stromal cell treatment in sheep. New Biotechnology. 25 September 2014. DOI: 10.1016/j.nbt.2014.07.004.
Impacto: 2.898. Cuartil: Q2
Fonseca C., Caminal M., Peris D., Barrachina J., Fàbregas P.J., Garcia F., Cairó J.J., Gòdia F., Pla A., Vives J.. An arthroscopic approach for the treatment of osteochondral focal defects with cell-free and cell-loaded PLGA scaffolds in sheep. Cytotechnology. March 2014. DOI: 10.1007/s10616-013-9581-3.
Impacto: 1.752. Cuartil: Q3
Caminal M., Moll X., Codina D., Rabanal R.M., Morist A., Barrachina J., Garcia F., Pla A., Vives J.. Transitory improvement of articular cartilage characteristics after implantation of polylactide:Polyglycolic acid (PLGA) scaffolds seeded with autologous mesenchymal stromal cells in a sheep model of critical-sized chondral defect. Biotechnology Letters. October 2014. DOI: 10.1007/s10529-014-1585-3.
Impacto: 1.591. Cuartil: Q3
Callejo J., Salvador C., González-Nuñez S., Almeida L., Rodriguez L., Marqués L., Valls A., Lailla J.M.. Live birth in a woman without ovaries after autograft of frozen-thawed ovarian tissue combined with growth factors. Journal of Ovarian Research. 2013. DOI: 10.1186/1757-2215-6-33.
Quesada-Gomez J.M., Diaz-Curiel M., Sosa-Henriquez M., Malouf-Sierra J., Nogues-Solan X., Gomez-Alonso C., Rodriguez-Mañas L., Neyro-Bilbao J.L., Cortes X., Delgadillo J.. Low calcium in take and inadequate vitamin D status in postmenopausal osteoporotic women. Journal of Steroid Biochemistry and Molecular Biology. 2013. DOI: 10.1016/j.jsbmb.2012.10.013.
Impacto: 4.049. Cuartil: Q2
Vélez R., Hernández-Fernández A., Caminal M., Vives J., Soldado F., Fernández A., Pla A., Aguirre M.. Treatment of femoral head osteonecrosis with advanced cell therapy in sheep. Archives of Orthopaedic and Trauma Surgery. November 2012. DOI: 10.1007/s00402-012-1584-6.
Impacto: 1.358. Cuartil: Q3
Avendaño Solá C., Delgadillo Duarte J., De Abajo F.J., Sanz N.. Changes in the European normative of clinical trials (II): Towards a proportional and risk-adapted regulation. Medicina Clinica. 12 May 2012. DOI: 10.1016/j.medcli.2011.12.010.
Impacto: 1.399. Cuartil: Q2
Avendaño Solá C., Delgadillo Duarte J., Pontes García C., Cabrera García L.. Changes in the European normative of clinical trials (i): A chance to improve the paperwork authorization. Medicina Clinica. 28 April 2012. DOI: 10.1016/j.medcli.2011.12.008.
Impacto: 1.399. Cuartil: Q2
Martinez-Zapata M.J., Martí-Carvajal A.J., Solà I., Expósito J.A., Bolíbar I., Rodríguez L., Garcia J.. Autologous platelet-rich plasma for treating chronic wounds.. Cochrane database of systematic reviews (Online). 2012. DOI: .
Impacto: 5.785. Cuartil: Q1
(1er decil)
Hook L., Vives J., Fulton N., Leveridge M., Lingard S., Bootman M.D., Falk A., Pollard S.M., Allsopp T.E., Dalma-Weiszhausz D., Tsukamoto A., Uchida N., Gorba T.. Non-immortalized human neural stem (NS) cells as a scalable platform for cellular assays. Neurochemistry International. September 2011. DOI: 10.1016/j.neuint.2011.06.024.
Impacto: 2.857. Cuartil: Q2
Uhde C.W., Vives J., Jaeger I., Li M.. Rmst is a novel marker for the mouse ventral mesencephalic floor plate and the anterior dorsal midline cells. PLoS ONE. 8 January 2010. DOI: 10.1371/journal.pone.0008641.
Impacto: 4.411. Cuartil: Q1
(1er decil)
Juanola S., Vives J., Milián E., Prats E., Cairó J.J., Gòdia F.. Expression of BHRF1 improves survival of murine hybridoma cultures in batch and continuous modes. Applied Microbiology and Biotechnology. May 2009. DOI: 10.1007/s00253-008-1820-8.
Impacto: 2.896. Cuartil: Q2
Cánovas M., Delgadillo J., Torres F., Riba N., Cebrecos J., Pelagio P., Cabré F.. Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 2009. DOI: 10.5414/CPP47124.
Impacto: 1.381. Cuartil: Q3
Martínez-Zapata M.J., Martí-Carvajal A., Solà I., Bolibar I., Ángel Expósito J., Rodriguez L., García J.. Efficacy and safety of the use of autologous plasma rich in platelets for tissue regeneration: A systematic review. Transfusion. January 2009. DOI: 10.1111/j.1537-2995.2008.01945.x.
Impacto: 2.982. Cuartil: Q2
Martinez-Zapata M.J., Martí-Carvajal A.J., Solà I., Exposito J.A., Bolivar I., Rodríguez L., Garcia J.. Autologous platelet rich-plasma for treating chronic wounds. Cochrane Database of Systematic Reviews. 2008. DOI: 10.1002/14651858.CD006899.
Impacto: 5.182. Cuartil: Q1
Vives J., Sasajala P., Kuo H., Zhao S., Li M.. A mouse model for tracking nigrostriatal dopamine neuron axon growth. Genesis. March 2008. DOI: 10.1002/dvg.20375.
Impacto: 2.217. Cuartil: Q3
Astori G., Larghero J., Bonfini T., Giancola R., Di Riti M., Rodriguez L., Rodriguez M., Mambrini G., Bigi L., Lacone A., Marolleau J., Panzani I., Garcia J., Querol S.. Ex vivo expansion of umbilical cord blood CD34<sup>+</sup> cells in a closed system: A multicentric study. Vox Sanguinis. April 2006. DOI: 10.1111/j.1423-0410.2006.00751.x.
Impacto: 2.111. Cuartil: N/D
Roussos I., Rodriguez M., Villán D., Ariza A., Rodriguez L., Garcia J.. Development of a rat model of spinal cord injury and cellular transplantation. Transplantation Proceedings. November 2005. DOI: 10.1016/j.transproceed.2005.09.185.
Impacto: 0.799. Cuartil: N/D
Rodríguez L., Velasco B., García J., Martín-Henao G.. Evaluation of an automated cell processing device to reduce the dimethyl sulfoxide from hematopoietic grafts after thawing. Transfusion. August 2005. DOI: 10.1111/j.1537-2995.2005.00213.x.
Impacto: 3.16. Cuartil: N/D
Rodríguez L., García J., Querol S.. Predictive utility of the attached segment in the quality control of a cord blood graft. Biology of Blood and Marrow Transplantation. April 2005. DOI: 10.1016/j.bbmt.2004.12.333.
Impacto: 3.561. Cuartil: N/D
Marín-Iranzo R., de la Siera-Iserte A., Roca-Cusachs A., Oliván-Martínez J., Redón-Mas J., Luque-Otero M., de la Figuera-von Wichman M., Pontes-García C., Delgadillo-Duarte J., Abellán J., Aracil J., Aranda P., Arrieta J., Artigao M., Ballvé J.L., Cano A., Divisón J.A., Fernández C., Fernández F., Gil-Extremera B., Gorostidi M., Guerediaga J., Jiménez M.J., Laporta F., Ledesma A., Liébana A., López de Coca E., María Orte L.M., Ocón J., Olmos J.R., Pascual J.M., Pladevall M., Plana J., Prieto M.A., Pujol M., Redón J., Robles Pérez N.R., Sobrino J., Suárez C., Tornero F., Combalía J., Terán M.. Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlopidine dose in essential hypertensive patients not controlled with amlodipine 5 mg. Revista Clinica Espanola. September 2005. DOI: 10.1157/13079069.
Impacto: 0.273. Cuartil: N/D
Rodriguez L., Azqueta C., Azzalin S., Garcia J., Querol S.. Washing of cord blood grafts after thawing: High cell recovery using an automated and closed system. Vox Sanguinis. October 2004. DOI: 10.1111/j.1423-0410.2004.00550.x.
Impacto: 1.762. Cuartil: N/D
de la Sierra A., Gil-Extremera B., Calvo C., Campo C., García-Puig J., Márquez E., Oliván J., Roca Cusachs A., Sanz de Castro S., Pontes C., Delgadillo J.. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. Journal of Human Hypertension. March 2004. DOI: 10.1038/sj.jhh.1001655.
Impacto: 1.93. Cuartil: N/D
Zhao S., Maxwell S., Jimenez-Beristain A., Vives J., Kuehner E., Zhao J., O'Brien C., De Felipe C., Semina E., Li M.. Generation of embryonic stem cells and transgenic mice expressing green fluorescence protein in midbrain dopaminergic neurons. European Journal of Neuroscience. March 2004. DOI: 10.1111/j.1460-9568.2004.03206.x.
Impacto: 3.82. Cuartil: N/D